Mexico: New evaluation option for new compositions
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: New evaluation option for new compositions

In February 2017, new guidelines were published by the Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) that should be followed by medicaments or drugs considered as new molecules before the new molecules committee for evaluation, including the non-person modalities.

Such guidelines define if a drug or medicine should be evaluated under the person modalities or non-person modalities, according to the current law and the risk, complexity or nature of the product.

It is worth mentioning that the committee of new molecules for evaluation define that a new molecule is a natural or synthetic substance that is an active drug in a medicine, not previously used in Mexico, wherein the safety, effectiveness and therapeutic uses are not completely documented in the scientific bibliography.

On the other hand, consider that the previous practice to evaluate a medicine was under person modalities, wherein the applicant for a drug or medicine together with his committee appear before the New Molecules Committee presenting the information to support the quality, safety and effectiveness of product.

With the non-person modalities, the applicant should prove to COFEPRIS the information to support the quality, safety and effectiveness of a product to be evaluated without appearing before the Committee of New Molecules.

The considerations that the applicant should take into account about the characteristics of the product are:

a) first marketing authorisation in the world;

b) new marketing authorisation in Mexico (product authorised by other country);

c) new combination with a fixed dose; and

d) therapeutic indication (including: bordering of therapeutic indication, changes in the treatment line).

If the product was evaluated by some international sanitary agency with which COFEPRIS has an agreement, the applicant should consider the option of non-present modalities. Some such agencies are the Food and Drug Administration of USA (FDA), Health Canada, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) and the Swiss Agency for Therapeutic Products (Swissmedic).

Agustin Azcatl

Olivares

Pedro Luis Ogazón No 17

Col San Angel

01000 México DF

Tel: +5255 53 22 30 00

Fax: +5255 53 22 30 01

olivlaw@olivares.com.mx

www.olivares.com.mx

more from across site and ros bottom lb

More from across our site

As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Pham Nghiem Xuan Bac, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Counsel explain how pricing flexibility, patent agents and being business partners can help them maintain profitable patent prosecution practices
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Speakers at an INTA event weighed in on why firms should create AI use policies and how they stay on top of the latest developments
The England and Wales Court of Appeal backed Lidl in its trademark dispute with Tesco, but we should pay more attention to how we rule on first-instance decisions
Richard Kempner, partner at Haseltine Lake Kempner, discusses the ‘remarkable’ comments from judges, despite the court finding against his client Tesco on the bulk of issues
Gift this article